PUMA BIOTECHNOLOGY, INC.PBYIEarnings & Financial Report
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
Revenue
$59.1M
Gross Profit
$45.2M
Operating Profit
$13.4M
Net Profit
N/A
Gross Margin
76.4%
Operating Margin
22.6%
Net Margin
N/A
YoY Growth
-18.2%
EPS
$0.40
PUMA BIOTECHNOLOGY, INC. Q4 FY2024 Financial Summary
PUMA BIOTECHNOLOGY, INC. reported revenue of $59.1M (down 18.2% YoY) for Q4 FY2024, with a net profit of N/A (N/A margin). Cost of goods sold was $13.9M, operating expenses totaled $31.8M.
Key Financial Metrics
| Total Revenue | $59.1M |
|---|---|
| Net Profit | N/A |
| Gross Margin | 76.4% |
| Operating Margin | 22.6% |
| Report Period | Q4 FY2024 |
Revenue Breakdown
PUMA BIOTECHNOLOGY, INC. Q4 FY2024 revenue of $59.1M breaks down across 2 segments, led by Products at $54.4M (92.0% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Products | $54.4M | 92.0% |
| Royalty | $4.7M | 8.0% |
PUMA BIOTECHNOLOGY, INC. Revenue by Segment — Quarterly Trend
PUMA BIOTECHNOLOGY, INC. revenue by segment across the last 4 reported quarters, showing how each business line (such as Products and Royalty) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Products | — | $51.9M | $49.2M | $43.1M |
| Royalty | — | $2.6M | $3.2M | $2.9M |
PUMA BIOTECHNOLOGY, INC. Annual Revenue by Year
PUMA BIOTECHNOLOGY, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $228.4M).
| Year | Annual Revenue |
|---|---|
| 2025 | $228.4M |
| 2024 | $230.5M |
| 2023 | $235.6M |
| 2022 | $228.0M |
PUMA BIOTECHNOLOGY, INC. Quarterly Revenue & Net Profit History
PUMA BIOTECHNOLOGY, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $75.5M | +27.7% | N/A | N/A |
| Q3 FY2025 | $54.5M | -32.4% | $8.8M | 16.2% |
| Q2 FY2025 | $52.4M | +11.4% | $5.9M | 11.2% |
| Q1 FY2025 | $46.0M | +5.1% | $3.0M | 6.5% |
| Q4 FY2024 | $59.1M | -18.2% | N/A | N/A |
| Q3 FY2024 | $80.5M | +43.5% | $20.3M | 25.2% |
| Q2 FY2024 | $47.1M | -13.7% | $-4.5M | -9.6% |
| Q1 FY2024 | $43.8M | -17.1% | $-4.8M | -11.0% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $43.8M | $47.1M | $80.5M | $59.1M | $46.0M | $52.4M | $54.5M | $75.5M |
| YoY Growth | -17.1% | -13.7% | 43.5% | -18.2% | 5.1% | 11.4% | -32.4% | 27.7% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $214.1M | $205.0M | $220.7M | $213.3M | $196.2M | $194.9M | $202.9M | $216.3M |
| Liabilities | $163.2M | $156.5M | $149.6M | $121.2M | $99.1M | $90.2M | $87.6M | $86.0M |
| Equity | $51.0M | $48.5M | $71.1M | $92.1M | $97.1M | $104.7M | $115.3M | $130.3M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $11.2M | $1.0M | $11.0M | $15.6M | $3.6M | $14.1M | $9.7M | $14.4M |